Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase 3 1

Status

Completed 2Active not recruiting 2Recruiting 1

Sponsor Class

OTHER 3INDUSTRY 2

Study Type

Interventional 5Observational 1

Sponsor

Cancer Type

Gynecologic 3Tumor-Agnostic 2

Conditions

Neoplasms 2Endometrial Neoplasms 2Ovarian Neoplasms 1Fallopian Tube Neoplasms 1

Interventions

Specimen Handling 613pembrolizumab 583Magnetic Resonance Spectroscopy 543Carboplatin 430Cyclophosphamide 380Cisplatin 377Biopsy 366Paclitaxel 314Nivolumab 312Gemcitabine 308Radiotherapy 268Bevacizumab 230Dexamethasone 217fludarabine 205Docetaxel 190durvalumab 188venetoclax 187Oxaliplatin 187Rituximab 174Fluorouracil 174atezolizumab 169Pemetrexed 166Capecitabine 162Radiosurgery 160Doxorubicin 160Radiation 156Ipilimumab 144Lenalidomide 140Leucovorin 138Etoposide 134

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Interventional × rucaparib × 90 days × Clear all
NCT03899155 2026-05-27

Pan Tumor Rollover Study

Bristol-Myers Squibb

Phase 2 Recruiting
1,500 enrolled
Tumor-Agnostic

Neoplasms

NCT03768063 2026-04-28

IMbrella B

Hoffmann-La Roche

Phase 3 Active not recruiting
1,000 enrolled
Tumor-Agnostic

Neoplasms

NCT03694262 2026-04-13

EndoBARR

Medical College of Wisconsin

Phase 2 Completed
30 enrolled 7 charts
Gynecologic

Endometrial Neoplasms

NCT02873962 2026-04-01

A Phase II Study Of Nivolumab/ Bevacizumab/Rucaparib

Dana-Farber Cancer Institute

Phase 2 Active not recruiting
72 enrolled 16 charts
Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT03617679 2026-03-24

Rucaparib vs Placebo Maintenance Therapy in Metastatic and Recurrent Endometrial Cancer

University of Colorado, Denver

Phase 2 Completed
79 enrolled 12 charts
Gynecologic

Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡